Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Feingold

Showing results (311-320 of 314) with videos related to

Pageof 32
Sort By:
You have reached the last page of results.This site can display upto 314 results.
Leukemia Research|June 11, 2020
Camidanlumab tesirine, an antibody-drug conjugate, in relapsed/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I studyAaron D Goldberg, Ehab Atallah, David Rizzieri, et al.
Blood|November 19, 2020
Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphomaMehdi Hamadani, John Radford, Carmelo Carlo-Stella, et al.
Nature Communications|September 1, 2025
Coagulation factor XII haploinsufficiency is protective against venous thromboembolism in a population-scale multidimensional analysisAmelia K Haj, David S Paul, Sean J Jurgens, et al.
The New England Journal of Medicine|May 8, 2024
Recombinant ADAMTS13 for Immune Thrombotic Thrombocytopenic PurpuraPavan K Bendapudi, Brody H Foy, Sarah B Mueller, et al.
Pageof 32

Showing results (311-320 of 314) with videos related to

Sort By:
Pageof 32
You have reached the last page of results.This site can display upto 314 results.
Leukemia Research|June 11, 2020
Camidanlumab tesirine, an antibody-drug conjugate, in relapsed/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I studyAaron D Goldberg, Ehab Atallah, David Rizzieri, et al.
Blood|November 19, 2020
Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphomaMehdi Hamadani, John Radford, Carmelo Carlo-Stella, et al.
Nature Communications|September 1, 2025
Coagulation factor XII haploinsufficiency is protective against venous thromboembolism in a population-scale multidimensional analysisAmelia K Haj, David S Paul, Sean J Jurgens, et al.
The New England Journal of Medicine|May 8, 2024
Recombinant ADAMTS13 for Immune Thrombotic Thrombocytopenic PurpuraPavan K Bendapudi, Brody H Foy, Sarah B Mueller, et al.
Pageof 32